Christine Yee Yan Wai
|Year of selection||2017|
|Institution||Faculty of Medicine, The Chinese University of Hong Kong|
Type of support
130 000 €
Food allergies affect around 1-3% of adults and 4-6% of children worldwide and studies show its prevalence is increasing. Allergic reactions to food can range from mild to severe, the worst of which is a sudden, potentially life-threatening condition called anaphylaxis. Globally, one of the most common triggers of food-induced anaphylactic reaction is shellfish. However, unlike for other common food allergens like peanuts, tree nuts and eggs, no effective treatment strategy exists. Instead, severe forms of the condition are managed by avoiding the allergen and using epinephrine auto-injectors if accidental exposure occurs. Dr. Christine Yee Yan Wai aims to remedy this shortcoming by developing a clinically useful approach for decreasing sensitivity to shellfish allergens. More specifically, her project seeks to apply a promising new strategy of therapy – antiallergic DNA vaccines – to shellfish allergy.
Allergen immunotherapy, also known as allergy shots, is a form of vaccination for allergic diseases.
Food allergies happen when the immune system overreacts to a particular protein found in a type of food. Allergy shots consist in giving patients gradually increasing doses of the substance to which they are allergic, leading to desensitization or even tolerance. Antiallergic DNA vaccines use the same mechanisms, but instead of the allergen itself, this type of immunotherapy involves the introduction into the body of plasmid DNA encoding for a less dangerous form of the allergen. « This novel method bears substantial benefits compared to conventional immunotherapy. In particular, it reduces the risk of anaphylactic shock during treatment and only requires two or three shots, whereas previous methods using native protein allergens required prolonged treatment duration », explains Dr. Christine Yee Yan Wai. Recognising the potential of this novel method to treat shellfish allergies, the researcher focused her PhD on developing an effective DNA vaccine and testing it on animal models with induced allergy. « Upon identifying the protein tropomyosin as the major shellfish allergen, we constructed MEM49, a hypoallergen with markedly diminished allergenicity. The delivery of MEM49-encoding DNA vaccine to mice pronouncedly ameliorated their allergic responses towards tropomyosin », she reports.
Developing an FDA approved DNA vaccine for shellfish allergies
« This project’s objective is to make the same thing feasible in humans », says Dr. Christine Yee Yan Wai. « Our aim is to construct a new DNA vaccine and adapt it to the standards of the U.S Food and Drug administration (FDA) ». To achieve their goal, Dr. Christine Yee Yan Wai and her team will first develop three new and clinically applicable constructs of the vaccine. Then, they will look at how theses vaccines work with human cells in vitro. « We are going to look closely at the mechanisms, look deep down into the cells and into the gene expression », she specifies. One of the most important aspects of the project is indeed its ambition to gain a better understanding of how DNA vaccines affect the immune system precisely. Lastly, once the “best” construct of the DNA vaccine is identified, it will be tested on mice models to assess its biodistribution, toxicity, safety and dose-dependent efficacy.
Severe shellfish allergy is a frequent, long-lasting and life-threatening disorder. Living with it significantly affects patients’ physical and social functioning, as well as their mental health. In Asia, where it is the most important food allergen, its prevalence is becoming worryingly high, especially in school children. Developing an effective treatment strategy is crucial if we want to improve the patients’ quality of life. Furthermore, the impact of food allergy on the economy is vast and growing, due to the heavy burden on health care expenditures, workplace, food industry and food regulatory agencies. Dr. Christine Yee Yan Wai’s project will not only help develop a safe and effective treatment but also provide important information for designing new therapeutical approaches for allergic patients in general.